INTRODUCTION {#s1}
============

Hypoxia is nowadays described as a hallmark of tumors \[[@R1], [@R2]\]. Tumor angiogenesis and glycolytic metabolism are two extensively studied responses of cancer cells to a deficit in oxygen \[[@R1]\]. The building of new blood vessels to bring O~2~ and the respiration-independent metabolism to survive under low O~2~ are actually complementary responses of tumors to hypoxia \[[@R1], [@R2]\]. These somehow opposite modes of adaptation account for local and temporal heterogeneities in tumor O~2~ distribution. The terms 'intermittent hypoxia' or 'cycling hypoxia' were settled to describe this phenomenon of fluctuating hypoxia in tumors \[[@R3], [@R4]\]. As a corollary, the extent of cycling hypoxia reflects tumor plasticity and thus measures the capacity of tumor cells to survive and proliferate in a hostile environment \[[@R3]\].

Although we and others have contributed to demonstrate the existence of cycles of hypoxia and/or ischemia in mouse, canine and human tumors \[see \[[@R5], [@R6]\] for review\], technologies aiming to routinely measure tumor O~2~ fluctuations in the clinics are not (yet) available despite important progresses in the *in vivo* imaging of hypoxia \[[@R7]-[@R11]\]. In the absence of readily accessible monitoring strategies, the analysis of the transcriptome associated with this phenomenon could represent a prognostic biomarker of cancer progression. Indeed, although mutations and defects in tumor suppressor genes directly influence the whole genetic profile of a given tumor cell clone, cycling hypoxia could be envisioned as a supra-oncogenic phenomenon influencing gene expression \[[@R3]\]. In other words, independently of the genetic background of tumor cells, cycling hypoxia has the potential to lead to common alterations in the expression of some transcripts, and thus to a possible clinically exploitable signature.

Clinical data sets derived from breast cancer patients could be used to evaluate the performance of such cycling hypoxia-related gene signature. The clinical and genetic heterogeneities of this disease and the very large panel of data sets available represent indeed good opportunities to evaluate new prognostic gene expression signatures \[[@R12]\]. Whole genome analysis already provided several molecular classifications for breast cancer beyond standard clinicopathologic variables \[[@R12]-[@R21]\]. The latter include tumor size, presence of lymph node metastasis and histological grades \[[@R22]\] but also encompass three predictive markers of response, namely expression of oestrogen (ER), progesterone (PR) and HER2 receptors \[[@R12]\]. Treatment guidelines are nowadays still largely based on algorithms integrating these informations such as the Notthingham Prognostic Index \[[@R22], [@R23]\] or Adjuvant! Online \[[@R24]\]. Accordingly, for early-stage breast cancer, adjuvant chemotherapy is recommended for most patients with ER-negative or HER2-positive tumors \[[@R13], [@R25]-[@R27]\]. The challenge actually resides in selecting patients with ER-positive HER2-negative disease who could benefit from chemotherapy.

In this study, we derived a transcriptomic signature of cycling hypoxia (CycHyp) using 20 cell lines derived from various human tumors and characterized by a large variety of distinct genetic anomalies. We then validated the capacity of the CycHyp signature to optimize patient stratification. In particular, we showed how the CycHyp signature could identify ER-positive node-negative breast cancer patients at high risk based on conventional NPI (and who could have been spared from chemotherapy) and inversely those patients classified at low risk but who could have drawn benefits of chemotherapy.

RESULTS {#s2}
=======

Identification of the CycHyp signature {#s2_1}
--------------------------------------

Tumor cells covering a large diversity of tissues ([Suppl. Table 1](#SD1){ref-type="supplementary-material"}) were submitted to cycling hypoxia (CycHyp) for 24 hours, maintained under normoxic conditions or exposed to continuous hypoxia (ContHyp) for the same period of time (Figure [1A](#F1){ref-type="fig"}). Corresponding mRNA samples were analysed by hybridization using Human Gene 1.0 ST Affymetrix microarrays. Gene expression profiles of each cell type under normoxia *vs.* cycling hypoxia (CycHyp) were produced to identify the most differentially expressed probesets. The CycHyp signature was determined as the top 100 probesets with the lowest FDR-corrected p-values averaged over 200 resamplings (Table [1](#T1){ref-type="table"}); a ContHyp signature was also determined in parallel (Table [2](#T2){ref-type="table"}). The heatmaps made with the 100 probe sets of the CycHyp signature confirmed its excellent potential of discrimination between cycling hypoxia and either normoxia (Figure [1B](#F1){ref-type="fig"}) or continuous hypoxia (Figure [1C](#F1){ref-type="fig"}). Moreover, Gene Set Enrichment Analysis (GSEA) \[[@R28]\] indicated that when considering differentially expressed probesets (after FDR correction), only 2 gene sets were significantly enriched in the CycHyp signature ([Suppl. Table 2](#SD1){ref-type="supplementary-material"}) whereas we identified 52 gene sets enriched in the ContHyp signature, including 17 directly related to hypoxia ([Suppl. Table 3](#SD1){ref-type="supplementary-material"}). Also, when using the MSigDB molecular signature database referring to hypoxia or HIF ([www.broadinstitute.org](http://www.broadinstitute.org)), we found 13 hypoxia gene sets sharing, on average, only 1.4 gene with CycHyp ([Suppl. Table 4](#SD1){ref-type="supplementary-material"}) whereas 44 hypoxia gene sets showed overlap with ContHyp with an average of 6.6 (1-27) common genes ([Suppl. Table 5](#SD1){ref-type="supplementary-material"}). We also compared the CycHyp signature to 13 other hypoxia-derived signatures described by Seigneuric et al. \[[@R29]\] and Starmans et al. \[[@R30]\]. The CycHyp signature was again far from those signatures with an average of only 1 gene in common. The overlap was larger between ContHyp and those signatures with an average of 6 genes in common ([Suppl. Table 6](#SD1){ref-type="supplementary-material"}). Finally, using TFactS \[[@R31]\] to analyse transcription factors regulating expression of genes associated to either signature, HIF-1α was only found as positively associated with the ContHyp signature.

###### Gene list of the CycHyp signature

        Probe     Entrez ID   GenBank           Symbol                                                                             Gene Title
  ----- --------- ----------- ----------------- ---------------------------------------------------------------------------------- ------------------------------------------------------------------------------
  1     8018860   332         NM_001168         BIRC5                                                                              baculoviral IAP repeat containing 5
  2     8064156   84619       NM_032527         ZGPAT [^\*^](#tfn_002){ref-type="table-fn"}                                        zinc finger, CCCH-type with G patch domain
  3     8138912   23658       NM_012322         LSM5[^§^](#tfn_003){ref-type="table-fn"}                                           LSM5 homolog, U6 small nuclear RNA associated (S. cerevisiae)
  4     7921786   5202        NM_012394         PFDN2                                                                              prefoldin subunit 2
  5     8165011   2219        NM_002003         FCN1                                                                               ficolin (collagen/fibrinogen domain containing) 1
  6     7964262   4666        NM_001113201      NACA[^\*^](#tfn_002){ref-type="table-fn"}                                          nascent polypeptide-associated complex alpha subunit
  7     7949792   5790        NM_005608         PTPRCAP [^\#^](#tfn_001){ref-type="table-fn"}                                      protein tyrosine phosphatase, receptor type, C-associated protein
  8     8034101   11018       NM_006858         TMED1                                                                              transmembrane emp24 protein transport domain containing 1
  9     8168087   3476        NM_001551         IGBP1                                                                              immunoglobulin (CD79A) binding protein 1
  10    7963575   1975        NM_001417         EIF4B§                                                                             eukaryotic translation initiation factor 4B
  11    8124397   3006        NM_005319         HIST1H1C [^\#^](#tfn_001){ref-type="table-fn"}                                     histone cluster 1, H1c
  12    7975989   81892       NM_031210         SLIRP[^§^](#tfn_003){ref-type="table-fn"}                                          SRA stem-loop interacting RNA binding protein
  13    8127692   3351        NM_000863         HTR1B                                                                              5-hydroxytryptamine (serotonin) receptor 1B
  14    8127087   2940        NM_000847         GSTA3                                                                              glutathione S-transferase alpha 3
  15    7941122   29901       NM_013299         SAC3D1                                                                             SAC3 domain containing 1
  16    7998692   4913        NM_002528         NTHL1                                                                              nth endonuclease III-like 1 (E. coli)
  17    8073623   758         NM_001044370      MPPED1                                                                             metallophosphoesterase domain containing 1
  18    8014865   4761        NM_006160         NEUROD2 [^\*^](#tfn_002){ref-type="table-fn"}                                      neurogenic differentiation 2
  19    8005726   3768        NM_021012         KCNJ12                                                                             potassium inwardly-rectifying channel, subfamily J, member 12
  20    7966631   64211       NM_022363         LHX5 [^\*^](#tfn_002){ref-type="table-fn"}                                         LIM homeobox 5
  21    8037853   54958       NM_017854         TMEM160                                                                            transmembrane protein 160
  22    8104136   3166        NM_018942         HMX1[^\*^](#tfn_002){ref-type="table-fn"}                                          H6 family homeobox 1
  23    7948606   746         NM_014206         C11orf10 [^\#^](#tfn_001){ref-type="table-fn"}                                     chromosome 11 open reading frame 10
  24    8044773   8685        NM_006770         MARCO                                                                              macrophage receptor with collagenous structure
  25    7947015   7251        NM_006292         TSG101                                                                             tumor susceptibility gene 101
  26    7931553   8433        NM_003577         UTF1 [^\*^](#tfn_002){ref-type="table-fn"}                                         undifferentiated embryonic cell transcription factor 1
  27    7956876   84298       NM_032338         LLPH                                                                               LLP homolog, long-term synaptic facilitation (Aplysia)
  28    8117372   8334        NM_003512         HIST1H2AC\#                                                                        histone cluster 1, H2ac
  29    8001329   869         NM_004352         CBLN1                                                                              cerebellin 1 precursor
  30    8027205   51079       NM_015965         NDUFA13                                                                            NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13
  31    8042896   3196        NM_016170         TLX2 [^\*^](#tfn_002){ref-type="table-fn"}                                         T-cell leukemia homeobox 2
  32    7911532   54998       NM_017900         AURKAIP1                                                                           aurora kinase A interacting protein 1
  33    8039923   54998       NM_017900         AURKAIP1                                                                           aurora kinase A interacting protein 1
  34    7992043   65990       BC001181          FAM173A                                                                            family with sequence similarity 173, member A
  35    8063074   90204       NM_080603         ZSWIM1 [^\*^](#tfn_002){ref-type="table-fn"}                                       zinc finger, SWIM-type containing 1
  36    7992191   23430       NM_012217         TPSD1                                                                              tryptase delta 1
  37    8108435   7322        NM_181838         UBE2D2                                                                             ubiquitin-conjugating enzyme E2D 2
  38    8165309   8721        NM_003792         EDF1 [^\*^](#tfn_002){ref-type="table-fn"}                                         endothelial differentiation-related factor 1
  39    7946267   63875       NM_022061         MRPL17                                                                             mitochondrial ribosomal protein L17
  40    7945536   51286       NM_016564         CEND1                                                                              cell cycle exit and neuronal differentiation 1
  41    8159609   8636        NM_003731         SSNA1 [^\#^](#tfn_001){ref-type="table-fn"}                                        Sjogren syndrome nuclear autoantigen 1
  42    8005471   6234        NM_001031         RPS28 [^\#^](#tfn_001){ref-type="table-fn"},[^§^](#tfn_003){ref-type="table-fn"}   ribosomal protein S28
  43    8025395   6234        NM_001031         RPS28                                                                              ribosomal protein S28
  44    7942824   6234        NM_001031         RPS28                                                                              ribosomal protein S28
  45    8170753   26576       NM_014370         SRPK3                                                                              SRSF protein kinase 3
  46    8032718   1613        NM_001348                                                                                            
  47    7967067   8655        NM_001037495                                                                                         
  48    8159654   25920       NM_015456         COBRA1 [^\*^](#tfn_002){ref-type="table-fn"}                                       cofactor of BRCA1
  49    8011212   6391        NM_003001         SDHC                                                                               succinate dehydrogenase complex, subunit C, integral membrane protein, 15kDa
  50    8011968   51003       NM_016060         MED31 [^\*^](#tfn_002){ref-type="table-fn"}                                        mediator complex subunit 31
  51    7977440   9834        NR_026800         KIAA0125                                                                           KIAA0125
  52    8016508   11267       NM_007241         SNF8 [^\*^](#tfn_002){ref-type="table-fn"}                                         SNF8, ESCRT-II complex subunit, homolog (S. cerevisiae)
  53    8168567   5456        NM_000307         POU3F4 [^\*^](#tfn_002){ref-type="table-fn"}                                       POU class 3 homeobox 4
  54    8086317   64689       NM_031899         GORASP1                                                                            golgi reassembly stacking protein 1, 65kDa
  55    8052834   54980       BC005079          C2orf42                                                                            chromosome 2 open reading frame 42
  56    8073334   9978        NM_014248         RBX1 [^\#^](#tfn_001){ref-type="table-fn"}                                         ring-box 1, E3 ubiquitin protein ligase
  57    7915846   8569        NM_003684         MKNK1                                                                              MAP kinase interacting serine/threonine kinase 1
  58    8071920   6634        NM_004175         SNRPD3 [^§^](#tfn_003){ref-type="table-fn"}                                        small nuclear ribonucleoprotein D3 polypeptide 18kDa
  59    8032371   81926       NM_031213         FAM108A1                                                                           family with sequence similarity 108, member A1
  60    7924884   8290        NM_003493         HIST3H3                                                                            histone cluster 3, H3
  61    8006845   6143        NM_000981         RPL19 [^§^](#tfn_003){ref-type="table-fn"}                                         ribosomal protein L19
  62    7946812   6207        NM_001017         RPS13 [^\#^](#tfn_001){ref-type="table-fn"},[^§^](#tfn_003){ref-type="table-fn"}   ribosomal protein S13
  63    7949015   65998       NM_001144936      C11orf95 [^\*^](#tfn_002){ref-type="table-fn"}                                     chromosome 11 open reading frame 95
  64    8009784   51081       NM_015971         MRPS7 [^§^](#tfn_003){ref-type="table-fn"}                                         mitochondrial ribosomal protein S7
  65    8174509   2787        NM_005274         GNG5                                                                               guanine nucleotide binding protein (G protein), gamma 5
  66    7906235   5546        NM_005973         PRCC [^§^](#tfn_003){ref-type="table-fn"}                                          papillary renal cell carcinoma (translocation-associated)
  67    8020179   57132       NM_020412         CHMP1B                                                                             chromatin modifying protein 1B
  68    7947450   4005        NM_005574         LMO2                                                                               LIM domain only 2 (rhombotin-like 1)
  69    8064370   6939        NM_004609         TCF15 [^\*^](#tfn_002){ref-type="table-fn"}                                        transcription factor 15 (basic helix-loop-helix)
  70    7955896   22818       NM_016057         COPZ1                                                                              coatomer protein complex, subunit zeta 1
  71    8137805   8379        NM_003550         MAD1L1 [^\#^](#tfn_001){ref-type="table-fn"}                                       MAD1 mitotic arrest deficient-like 1 (yeast)
  72    8117334   8359        NM_003538         HIST1H4A [^\#^](#tfn_001){ref-type="table-fn"}                                     histone cluster 1, H4a
  73    8117368   8364        NM_003542         HIST1H4C [^\#^](#tfn_001){ref-type="table-fn"}                                     histone cluster 1, H4c
  74    7977507   85495       NR_002312         RPPH1[^§^](#tfn_003){ref-type="table-fn"}                                          ribonuclease P RNA component H1
  75    7949410   378938      BC018448          MALAT1                                                                             metastasis associated lung adenocarcinoma transcript 1 (non-protein coding)
  76    8150433   157848      NM_152568         NKX6-3 [^\*^](#tfn_002){ref-type="table-fn"}                                       NK6 homeobox 3
  77    8071168   29797       NR_024583         POM121L8P                                                                          POM121 membrane glycoprotein-like 8 pseudogene
  78    7989611   84191       NM_032231         FAM96A                                                                             family with sequence similarity 96, member A
  79    7980859               NM_001080113                                                                                         
  80    8032782   126259      NM_144615         TMIGD2                                                                             transmembrane and immunoglobulin domain containing 2
  81    8110861   64979       NM_032479         MRPL36 [^§^](#tfn_003){ref-type="table-fn"}                                        mitochondrial ribosomal protein L36
  82    7901687   199964      NM_182532         TMEM61                                                                             transmembrane protein 61
  83    7916130   112970      NM_138417         KTI12                                                                              KTI12 homolog, chromatin associated (S. cerevisiae)
  84    8048712   440934      BC033986          LOC440934                                                                          hypothetical LOC440934
  85    8018993   146713      NM_001082575      RBFOX3 [^§^](#tfn_003){ref-type="table-fn"}                                        RNA binding protein, fox-1 homolog (C. elegans) 3
  86    8032601   84839       NM_032753         RAX2                                                                               retina and anterior neural fold homeobox 2
  87    8010719   201255      NM_144999         LRRC45                                                                             leucine rich repeat containing 45
  88    8036584   3963        NM_002307         LGALS7                                                                             lectin, galactoside-binding, soluble, 7
  89    8133209   441251      NR_003666         SPDYE7P                                                                            speedy homolog E7 (Xenopus laevis), pseudogene
  90    8159501   286256      NM_178536         LCN12                                                                              lipocalin 12
  91    8028546   3963        NM_002307         LGALS7                                                                             lectin, galactoside-binding, soluble, 7
  92    8065013               ENST00000427835                                                                                      
  93    8018502   201292      NM_173547         TRIM65 [^\*^](#tfn_002){ref-type="table-fn"}                                       tripartite motif containing 65
  94    7903294   64645       NM_033055         HIAT1                                                                              hippocampus abundant transcript 1
  95    7989473   388125      NM_001007595      C2CD4B                                                                             C2 calcium-dependent domain containing 4B
  96    8054449   644903      AK095987          FLJ38668                                                                           hypothetical LOC644903
  97    8081867   51300       NM_016589         TIMMDC1                                                                            translocase of inner mitochondrial membrane domain containing 1
  98    7934544   118881      NM_144589         COMTD1                                                                             catechol-O-methyltransferase domain containing 1
  99    7968260   219409      NM_145657         GSX1 [^\*^](#tfn_002){ref-type="table-fn"}                                         GS homeobox 1
  100   8022952   56853       NM_020180         CELF4 [^§^](#tfn_003){ref-type="table-fn"}                                         CUGBP, Elav-like family member 4

^\#^ common to the ContHyp signature

^\*^ regulators of transcription

^§^ involved in RNA processing

###### Gene list of the ContHyp signature

        Probe     Entrez ID   GenBank           Symbol       Gene Title
  ----- --------- ----------- ----------------- ------------ -----------------------------------------------------------------------------------------------------------
  1     7948606   746         NM_014206         C11orf10     chromosome 11 open reading frame 10
  2     8043283   55818       NM_018433         KDM3A        lysine (K)-specific demethylase 3A
  3     8025395   6234        NM_001031         RPS28        ribosomal protein S28
  4     8139706   23480       NM_014302         SEC61G       Sec61 gamma subunit
  5     7942824   6234        NM_001031         RPS28        ribosomal protein S28
  6     8005471   6234        NM_001031         RPS28        ribosomal protein S28
  7     8048489   55139       NM_018089         ANKZF1       ankyrin repeat and zinc finger domain containing 1
  8     7994737   226         NM_000034         ALDOA        aldolase A, fructose-bisphosphate
  9     7934278   5033        NM_000917         P4HA1        prolyl 4-hydroxylase, alpha polypeptide I
  10    8102518   401152      NM_001170330      C4orf3       chromosome 4 open reading frame 3
  11    8117334   8359        NM_003538         HIST1H4A     histone cluster 1, H4a
  12    8074969   1652        NM_001355         DDT          D-dopachrome tautomerase
  13    8044766   51141       NM_016133         INSIG2       insulin induced gene 2
  14    7937476   6181        NM_001004         RPLP2        ribosomal protein, large, P2
  15    8086961   5210        NM_004567         PFKFB4       6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4
  16    8145454   665         NM_004331         BNIP3L       BCL2/adenovirus E1B 19kDa interacting protein 3-like
  17    8113981   8974        NM_004199         P4HA2        prolyl 4-hydroxylase, alpha polypeptide II
  18    8162142   81689       NM_030940         ISCA1        iron-sulfur cluster assembly 1 homolog (S. cerevisiae)
  19    8007992   3837        NM_002265         KPNB1        karyopherin (importin) beta 1
  20    7928308   54541       NM_019058         DDIT4        DNA-damage-inducible transcript 4
  21    8073334   9978        NM_014248         RBX1         ring-box 1, E3 ubiquitin protein ligase
  22    8124397   3006        NM_005319         HIST1H1C     histone cluster 1, H1c
  23    8153459   65263       NM_023078         PYCRL        pyrroline-5-carboxylate reductase-like
  24    7916568               AF263547                       
  25    7955117   23519       NM_012404         ANP32D       acidic (leucine-rich) nuclear phosphoprotein 32 family, member D
  26    8098604   353322      NM_181726         ANKRD37      ankyrin repeat domain 37
  27    8121076   10957       NM_006813         PNRC1        proline-rich nuclear receptor coactivator 1
  28    7921076   54865       NM_182679         GPATCH4      G patch domain containing 4
  29    7908879   8497        NM_015053         PPFIA4       protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4
  30    8103518   23520       NM_012403         ANP32C       acidic (leucine-rich) nuclear phosphoprotein 32 family, member C
  31    8050591   91942       NM_174889         NDUFAF2      NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, assembly factor 2
  32    8172154   6187        NM_002952         RPS2         ribosomal protein S2
  33    7984846   1198        NM_001130028      CLK3         CDC-like kinase 3
  34    7946812   6207        NM_001017         RPS13        ribosomal protein S13
  35    7982531   8125        NM_006305         ANP32A       acidic (leucine-rich) nuclear phosphoprotein 32 family, member A
  36    8119898   7422        NM_001025366      VEGFA        vascular endothelial growth factor A
  37    8004331   9744        NM_014716         ACAP1        ArfGAP with coiled-coil, ankyrin repeat and PH domains 1
  38    8159441   29085       NM_001135861      PHPT1        phosphohistidine phosphatase 1
  39    8168500   5230        NM_000291         PGK1         phosphoglycerate kinase 1
  40    7938890   10196       NM_005788         PRMT3        protein arginine methyltransferase 3
  41    7930398   4601        NM_005962         MXI1         MAX interactor 1
  42    7997740   81631       NM_022818         MAP1LC3B     microtubule-associated protein 1 light chain 3 beta
  43    8004360   147040      NM_001002914      KCTD11       potassium channel tetramerisation domain containing 11
  44    7909782   51018       NM_016052         RRP15        ribosomal RNA processing 15 homolog (S. cerevisiae)
  45    7949792   5790        NM_005608         PTPRCAP      protein tyrosine phosphatase, receptor type, C-associated protein
  46    8124385   8366        NM_003544         HIST1H4B     histone cluster 1, H4b
  47    8117368   8364        NM_003542         HIST1H4C     histone cluster 1, H4c
  48    8081241   84319       NM_032359         C3orf26      chromosome 3 open reading frame 26
  49    8050079   246243      NM_002936         RNASEH1      ribonuclease H1
  50    8005765   26118       NM_015626         WSB1         WD repeat and SOCS box containing 1
  51    7924491   64853       NM_022831         AIDA         axin interactor, dorsalization associated
  52    8133273               ENST00000455206                
  53    8124391   8335        NM_003513         HIST1H2AB    histone cluster 1, H2ab
  54    8159609   8636        NM_003731         SSNA1        Sjogren syndrome nuclear autoantigen 1
  55    7957890   27340       NM_014503         UTP20        UTP20, small subunit (SSU) processome component, homolog (yeast)
  56    7933582   100287932   NM_006327         TIMM23       translocase of inner mitochondrial membrane 23 homolog (yeast)
  57    8153002   10397       NM_001135242      NDRG1        N-myc downstream regulated 1
  58    7926037   5209        NM_004566         PFKFB3       6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3
  59    8082066   26355       NM_014367         FAM162A      family with sequence similarity 162, member A
  60    8042962   9801        NM_014763         MRPL19       mitochondrial ribosomal protein L19
  61    8090678   11222       NM_007208         MRPL3        mitochondrial ribosomal protein L3
  62    7977507   85495       NR_002312         RPPH1        ribonuclease P RNA component H1
  63    8007397   10197       NM_176863         PSME3        proteasome (prosome, macropain) activator subunit 3 (PA28 gamma/ Ki)
  64    7998902   54985       NM_017885         HCFC1R1      host cell factor C1 regulator 1 (XPO1 dependent)
  65    8117372   8334        NM_003512         HIST1H2AC    histone cluster 1, H2ac
  66    7997230   5713        NM_002811         PSMD7        proteasome (prosome, macropain) 26S subunit, non-ATPase, 7
  67    7915485   10969       NM_006824         EBNA1BP2     EBNA1 binding protein 2
  68    8113873   3094        NM_005340         HINT1        histidine triad nucleotide binding protein 1
  69    7958152   5223        NM_002629         PGAM1        phosphoglycerate mutase 1 (brain)
  70    7947867   5702        NM_002804         PSMC3        proteasome (prosome, macropain) 26S subunit, ATPase, 3
  71    7964460   1649        NM_004083         DDIT3        DNA-damage-inducible transcript 3
  72    7928395   170384      NM_173540         FUT11        fucosyltransferase 11 (alpha (1,3) fucosyltransferase)
  73    8163629   944         NM_001244         TNFSF8       tumor necrosis factor (ligand) superfamily, member 8
  74    7965486   51134       NM_016122         CCDC41       coiled-coil domain containing 41
  75    8136179   23008       AF277175          KLHDC10      kelch domain containing 10
  76    8095870   901         NM_004354         CCNG2        cyclin G2
  77    8127526   6170        NM_001000         RPL39        ribosomal protein L39
  78    8174710   6170        NM_001000         RPL39        ribosomal protein L39
  79    8137517   3361        NM_024012         HTR5A        5-hydroxytryptamine (serotonin) receptor 5A
  80    7929624   5223        NM_002629         PGAM1        phosphoglycerate mutase 1 (brain)
  81    8052331   87178       NM_033109         PNPT1        polyribonucleotide nucleotidyltransferase 1
  82    8015969   7343        NM_014233         UBTF         upstream binding transcription factor, RNA polymerase I
  83    8069168   386685      NM_198699         KRTAP10-12   keratin associated protein 10-12
  84    7941087   5526        NM_006244         PPP2R5B      protein phosphatase 2, regulatory subunit B\', beta
  85    8026875   26780       NR_000012         SNORA68      small nucleolar RNA, H/ACA box 68
  86    8027621   2821        NM_000175         GPI          glucose-6-phosphate isomerase
  87    8130539   117289      NM_054114         TAGAP        T-cell activation RhoGTPase activating protein
  88    8004691   92162       NM_203411         TMEM88       transmembrane protein 88
  89    7962183   205         NM_001005353      AK4          adenylate kinase 4
  90    8137805   8379        NM_003550         MAD1L1       MAD1 mitotic arrest deficient-like 1 (yeast)
  91    8124388   8358        NM_003537         HIST1H3B     histone cluster 1, H3b
  92    8083223   205428      NM_173552         C3orf58      chromosome 3 open reading frame 58
  93    8113305   1105        NM_001270         CHD1         chromodomain helicase DNA binding protein 1
  94    8169659   4694        NM_004541         NDUFA1       NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1, 7.5kDa
  95    8046408   5163        NM_002610         PDK1         pyruvate dehydrogenase kinase, isozyme 1
  96    8053599   23559       NM_012477         WBP1         WW domain binding protein 1
  97    8043377   23559       NM_012477         WBP1         WW domain binding protein 1
  98    7960878   642559      GU480887          POU5F1P3     POU class 5 homeobox 1 pseudogene 3
  99    7959023   643246      NM_001085481      MAP1LC3B2    microtubule-associated protein 1 light chain 3 beta 2
  100   8073148   468         NM_001675         ATF4         activating transcription factor 4 (tax-responsive enhancer element B67)

![The CycHyp and ContHyp signatures\
(A.) Flowchart of the signature determination from tumor cells exposed either to normoxia, cycling or continuous hypoxia. (B.) Heatmap depicting the transcripts from the CycHyp signature either underexpressed (green) or overexpressed (red) (centered to median values). Each column corresponds to a specific human Gene 1.0 ST probeset ; each line represents a specific cell line either maintained under normoxia (black label) or exposed to cycling hypoxia (red label); cells under normoxia and cycling hypoxia are perfectly separated in two distinct clusters, except for one cycling hypoxia sample in the normoxia cluster. (C.) Similarly, a heatmap depicting the relative expression of transcripts from the CycHyp signature in the cell lines maintained under continuous hypoxia (blue) or cycling hypoxia (red); only two cycling hypoxia samples are grouped with the continuous hypoxia samples.](oncotarget-05-6947-g001){#F1}

The CycHyp signature predicts clinical outcome in breast cancer patients {#s2_2}
------------------------------------------------------------------------

To evaluate the prognostic value of the CycHyp signature, we focused on breast cancer because of the very large amounts of well-annotated clinical data sets available and a clearly identified need to discriminate between patients at low and high risks among subgroups determined on the basis of clinicopathologic criteria \[[@R12], [@R13]\]. Publicly available GEO data sets allowed us to collect information on the survival of 2,150 patients with primary breast cancer (see clinical features in Table [3](#T3){ref-type="table"}).

###### Breast Cancer Patient Demographics and Characteristics

  --------------------------------------------------------------------------------------------------------
                      All patients\   ER+/HER2-\   ER+/HER2- Node neg.\   ER+/HER2- Node neg. Untreated\
                      n = 2150\       n=1452\      n=899\                 n=590\
                      No  %           No  %        No  %                  No  %
  ------------------- --------------- ------------ ---------------------- --------------------------------
  Age                                                                     

  ≤50\                649  30\        388  27\     218  24\               190  32\
  \>50\               945  44\        649  45\     367  41\               237  40\
  NA                  556  26         415  28      314  35                163  28

  \                                                                       
  Tumor size                                                              

  ≤2cm\               742  35\        537  37\     474  53\               424  72\
  \>2cm\              473  22\        326  22\     210  23\               158  28\
  NA                  935  43         589  41      215  24                8  1

  \                                                                       
  Grade                                                                   

  0-1\                224  10\        200  14\     148  17\               104  18\
  2\                  605  28\        485  33\     346  38\               270  46\
  3\                  487  23\        206  14\     162  18\               137  23\
  NA                  834  39         561  39      243  27                79  13

  \                                                                       
  Node status                                                             

  Negative\           1329  62\       899  62\     899  100\              590  100\
  Positive            821  38         553  38      0  0                   0  0

  \                                                                       
  Estrogen receptor                                                       

  Negative\           443  21\        0  0\        0  0\                  0  0\
  Positive\           1607  75\       1452  100\   899  100\              590  100\
  NA                  100  4          0  0         0  0                   0  0

  \                                                                       
  HER2 status                                                             

  Negative\           1835  85\       1452  100\   899  100\              590  100\
  Positive            315  15         0  0         0  0                   0  0

  \                                                                       
  Treatment                                                               

  None\               901  42\        590  41\     590  66\               590  100\
  Chemotherapy\       691  32\        410  28\     73  8\                 0  0\
  Hormonotherapy      558  26         452  31      236  26                0  0
  --------------------------------------------------------------------------------------------------------

Data obtained from GSE11121 (n=200), GSE17705 (n=298), GSE2034/5327 (n=344), GSE20685 (n=327), GSE21653 (n=253), GSE2990 (n=138), GSE3494 (n=178), GSE6532 (n=214), and GSE7390 (n=198). NA = Not Available.

In order to exploit these data sets, we first transferred the Gene 1.0ST datasets in the HU133 platform. We then used the VDX dataset (GSE2034 and GSE5327) as a reference because of its large number of node negative untreated patients \[[@R17]\]. This training dataset was used to estimate a prognostic multivariate Cox proportional hazard model built on the CycHyp signature (see Methods for details). The other eight datasets (see references in Table [3](#T3){ref-type="table"}) were used according to the methodology described by Haibe-Kains and colleagues \[[@R32]\], to assess the prognostic performance of the CycHyp signature on independent samples. We first chose to evaluate our signature independently of the clinicopathological data. The prognostic potential of the CycHyp signature to discriminate between patients at low or high risk was confirmed with a HR=2.39 and a p-value = 1.13e-18 whathever the treatment and the tumor histology (Figure [2A](#F2){ref-type="fig"}). We then focused on the ER+ HER2- population which is known to be heterogeneous and thus difficult to treat \[[@R12], [@R13]\]. The discriminating capacity of the CycHyp signature remained strikingly high in the ER+ HER2- patient populations (HR = 2.47, p-value = 3.88e-13, Figure [2B](#F2){ref-type="fig"}). Finally, among this subpopulation of patients, we considered those with a node negative status (Figure [2C](#F2){ref-type="fig"}) and among the latter, those who did not receive any treatment (Figure [2D](#F2){ref-type="fig"}). Hazard ratios rose to 3.16 and 5.54 in these conditions (p-values = 2.85e-9 and 6.44e-10, respectively), further supporting the discriminating potential of the CycHyp signature. In particular, the data presented in Figure [2D](#F2){ref-type="fig"} allowed to exclude any confounding influence of the potential benefit arising from the treatment administered to these patients and thus clearly identified a population of patients who remained inadequately untreated.

![Kaplan-Meier survival curves of patients with primary breast cancer, as determined by using the CycHyp signature\
(A) All patients. (B.) ER+/HER2- patients, (C.) node-negative ER+/HER2-, (D.) node-negative, untreated ER+/HER2- patients (DFS Mantel-Cox comparison); hazard ratio (HR), balanced classification rate (BCR) and concordance index (C-index) for the prediction in high risk *vs.* low risk groups are reported; HRs are presented with their associated p-values.](oncotarget-05-6947-g002){#F2}

Using the same methodology, we examined the prognostic capacity of the ContHyp signature (discriminating between normoxia and continuous hypoxia). The performance of the ContHyp signature was satisfactory on the ER+ HER2- untreated population (HR = 2.58, p-value = 1.46e-4, see [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}) but was significantly lower (p-value = 3.61e-8) than the CycHyp signature.

The CycHyp signature provides significant additional prognostic information to available multigene assays {#s2_3}
---------------------------------------------------------------------------------------------------------

To evaluate the performance of the CycHyp signature, we compared it with other well-established prognostic multigene assays for breast cancer, namely Gene70 or Mammaprint \[[@R14]\], Gene76 \[[@R17]\] and Oncotype Dx \[[@R15]\]. Using the same set of ER+ HER2- node negative patients as used in Figure [2D](#F2){ref-type="fig"}, we could determine the low *vs.* high risk patient stratification according to these signatures. The superior prognostic potential of the CycHyp signature could be captured from the Kaplan Meier curves obtained with the Gene 70, Gene76 and Oncotype DX signatures (compare Figure [3A](#F3){ref-type="fig"} with Figure [2D](#F2){ref-type="fig"}). Hazard ratios confirmed the net advantage of the CycHyp signature with a significantly higher value than the three other metagenes (Figure [3B](#F3){ref-type="fig"}). The concordance index, which is the probability of a high risk patient to relapse before a low risk patient, was also higher with the CycHyp signature (Figure [3B](#F3){ref-type="fig"}). Finally, the Balanced Classification Rate (BCR), which represents the average between sensitivity and specificity to discriminate between patients with progressing disease *vs.* disease-free at 5 years, was significantly higher for the CycHyp signature than the three other multigene assays (Figure [3B](#F3){ref-type="fig"}). The sensitivity of the CycHyp was above 80% and the specificity of the CycHyp signature was well above the level of the others (Figure [3B](#F3){ref-type="fig"}). Of note, the metrics corresponding to each data set taken separately is depicted in [Suppl. Figure 2](#SD1){ref-type="supplementary-material"}.

![Comparison of the prognostic potential of the CycHyp signature vs. Gene 70 (Mammaprint), Gene 76 and Oncotype Dx signatures\
(A) Kaplan-Meier survival curves of node-negative, untreated ER+/HER2- patients, as determined by using the indicated signature (DFS Mantel-Cox comparison); hazard ratio (HR), balanced classification rate (BCR) and C-index for the prediction in high risk *vs.* low risk groups are reported; HR are presented with their associated p-values. (B.) Forest plots of the hazard ratio (HR), Concordance index (CI), balance classification rate (BCR), sensitivity and specificity for the prediction in high risk *vs.* low risk groups; p-values refer to the comparisons of CycHyp *vs.* Gene 70 (Mammaprint), Gene 76 and Oncotype Dx. (C.) Graph represents the power of discrimination in high *vs.* low risk groups (expressed as the logarithm of the p-values of the logrank) of the ContHyp and CycHyp signatures (see red dots) versus 1,000 randomly generated signatures (yellow shapes depicting their distribution).](oncotarget-05-6947-g003){#F3}

Importantly, to further validate the prognostic significance of the CycHyp signature, a comparison with random gene signatures was performed according to the methodology described by Venet et al. \[[@R33]\] and Beck et al. \[[@R34]\]. Figure [3C](#F3){ref-type="fig"} shows the distribution of the p-values (logrank test in log 10) for 1000 randomly generated signatures together with the p-values of the CycHyp and ContHyp signatures. The logrank test (or Mantel-Haenszel test) \[[@R35]\] is commonly used to assess whether there is a significant survival difference between risk groups. The discrimination between risk groups was significantly higher (P \< 0.001) with the CycHyp signature as compared to each of the random signatures whereas the ContHyp signature was not significantly better (vs. random ones; P=0.141). The same analysis was carried out for the three other metrics (HR, CI and BCR) to assess the discrimination capability between risk groups and confirmed the significantly higher value of the CycHyp signature (vs. random signatures) ([Suppl. Figure 3](#SD1){ref-type="supplementary-material"}).

The CycHyp signature in association with NPI offers a powerful prognostic tool {#s2_4}
------------------------------------------------------------------------------

We then aimed to determine whether the CycHyp signature could improve the Nottingham Prognostic Index (NPI) for better predicting the survival of operable breast cancers. The NPI algorithm combines nodal status, tumour size and histological grade and allows to model a *continuum* of clinical aggressiveness with 3 subsets of patients divided into good, moderate, and poor prognostic groups with 15-year survival \[[@R22], [@R23], [@R36]\]. Since few patients were assigned a poor index, we merged here the moderate and poor indices into a high risk group to facilitate the comparison with the CycHyp signature. We found that by integrating the CycHyp signature, an important proportion of patients could be reclassified to another risk group (Figure [4](#F4){ref-type="fig"}). 44.1% of patients classified at high risk using the NPI algorithm were identified at low risk when using the CycHyp signature and were confirmed to be "false positive" since they actually exhibited a profile of survival closer to the low risk NPI patient (Figure [4A](#F4){ref-type="fig"}). Inversely, using the CycHyp signature, we also identified in the patients at low risk based on the NPI criteria, 33.1% of patients with a risk profile closer to the patients with a negative outcome (Figure [4B](#F4){ref-type="fig"}). This increased discriminating potential remained highly relevant when considering all patients or patients with a ER+ HER2- status (and among the latter, those with a node negative status or the untreated ones) (see [Suppl. Figure 4](#SD1){ref-type="supplementary-material"}).

![Kaplan-Meier survival curves of node-negative, untreated ER+/HER2- patients stratified by using the CycHyp signature to detect\
(A.) false positive patients among those identified at high risk based on the NPI nomenclature and (B.) false negative patients among those identified at low risk based on the NPI nomenclature (DFS Mantel-Cox comparison).](oncotarget-05-6947-g004){#F4}

DISCUSSION {#s3}
==========

This study demonstrates that a gene signature derived from the transcriptomic adaptation of tumor cells to cycling hypoxia is prognostic of breast cancer. The CycHyp signature that we have identified and validated in this study has not only prognostic value independently of molecular risk factors but also provides significant additional prognostic information to clinicopathologic criteria. Clinical outcome of breast cancer patients is nowadays largely based on histological grade and the status of ER, PR, and HER2 receptors \[[@R12], [@R13], [@R22]\]. In early breast cancer, a lack of expression of ER (and PR) will almost systematically lead to the administration of adjuvant chemotherapy in addition to locoregional treatment \[[@R12], [@R25], [@R26]\]. Also, for patients with a tumor expressing HER2, chemotherapy and/or trastuzumab represents the option the most likely to be beneficial based on current clinical knowledge \[[@R12]\]. The impact of chemotherapy is actually more difficult to anticipate for the rest of early-stage breast cancer patients, i.e. those diagnosed with a ER-positive and HER2-negative disease. These patients represent indeed a wide spectrum of different risk profiles: for women with high-risk disease, if chemotherapy is appropriate, others will derive little benefit from it. Our study therefore represents a significant advance for this population of patients, which consists of two third of all breast cancers. We have indeed demonstrated that the CycHyp signature outperforms the existing major prognostic gene expression signatures and offers a unique decision making tool to complement the discrimination of breast cancer patients based on anatomopathologic evaluation.

More generally, the excellent prognostic value of CycHyp confirms the link between cycling hypoxia and cancer aggressiveness \[[@R4], [@R5]\]. This gives credentials to the phenotypic adaptation of tumors resulting from heterogeneities in blood flow distribution as a trigger of cancer progression \[[@R3], [@R4]\]. Also, with the recent impetus in the understanding of tumor metabolism \[[@R37], [@R38]\], it has become obvious that the capacity of a given tumor cell to survive in both aerobic and anaerobic environments represents a critical advantage \[[@R39]-[@R41]\]. Interestingly, our study also documents the higher prognostic value of a transcriptomic signature derived from cycling hypoxia *vs.* continuous hypoxia. This confirms that although hypoxia is a frequent feature of poor-prognosis tumors and was reported to drive gene signature associated with negative outcome \[[@R42]-[@R45]\], prognostic markers integrating fluctuations in the hypoxic status of tumors (this study) introduce an additional layer of complexity that better fits the *in vivo* situation.

Whether the CycHyp signature encompasses genes that actively drive cancer progression or reflects a context of metabolic and hypoxic stress favorable to increased mutagenesis and genetic instability \[[@R3]\], warrants further studies. A few hints can however be gleaned from the comparison of the different signatures.

First, the comparison of the CycHyp and ContHyp signatures indicates that the cycling nature of hypoxia leads to specific alterations in mRNA expression since only 11 common transcripts were found in the two gene lists (see symbols \# in Table [1](#T1){ref-type="table"}). Furthermore, among these 11 genes, most encode for proteins involved in housekeeping functions such as chromatin packaging (HIST1H 1C, 2AC, 4A and 4C) and RNA processing (RPS13 and 28). The only gene common to the two signatures with a known function related to hypoxia is RBX1 or E3 ubiquitin ligase which mediates the ubiquitination and subsequent proteasomal degradation of target proteins \[[@R46]\], including the misfolded proteins known to accumulate under low pO~2~. Besides the RBX1 gene, the CycHyp signature does not actually contain genes known to be consistently regulated in response to chronic hypoxia. By contrast, the ContHyp signature contains 14 genes already reported to be overexpressed under low pO~2~ and even directly under the control of the transcription factor HIF-1α, including those coding for glucose metabolism enzymes (ALDOA, PFKB3, PFKB4, PGK1, PGAM1, GPI) and the angiogenic growth factor VEGFA. This HIF-dependent gene expression program of the ContHyp signature was actually confirmed in the GSEA and MSigBD analyses and was consistent with previously reported hypoxia-driven gene signatures \[[@R42], [@R44], [@R45]\]. More generally, these findings position the CycHyp signature far from the conventional hypoxia-derived signatures \[[@R29], [@R30]\] but instead as a biomarker of a distinct tumor biology process involving adaptation to fluctuations in the tumor microenvironment.

Second, a large amount of transcripts of the CycHyp signature encode for proteins themselves involved in the regulation of transcription. Data mining revealed that more than 18 transcripts of the CycHyp signature are transcription factors/regulators and 13 others are directly involved in RNA processing (see symbols \* and § in Table [1](#T1){ref-type="table"}, respectively). This represents one third of the genes comprising the CycHyp signature and reflects a major difference with the ContHyp signature. While hypoxia is usually associated with cell cycle arrest and mTOR inhibition, cycling hypoxia may be compatible with a maintained proliferation potential. This is further supported by the suppression of geroconversion (ie, the process leading from proliferative arrest to irreversible senescence) observed in response to hypoxia \[[@R47], [@R48]\] that offers tumor cells the opportunity to re-enter cell cycle when O~2~ is again available. Further studies are needed to compare the evolution of mTOR activity and mTOR-dependent genes (including those encoding for ribosomal proteins) during cycling and continuous hypoxia.

Finally, the *in vitro* conditions at the origin of the establishment of the CycHyp signature may actually have specific bearing on its robustness and applicability. Indeed, we previously documented that fluctuating oxygen levels could also directly impact endothelial cells within a tumor \[[@R49], [@R50]\] indicating that non-tumor cells may also contribute to the same transcriptomic adaptation as tumor cells, thereby reinforcing the relevance of the CycHyp signature. Also, although we have used the CycHyp signature as a prognostic biomarker for early-stage breast cancer, this signature was identified by integrating the information arising from tumor cells of various origins and characterized by various oncogenic alterations; the prognostic value of the CycHyp signature in other cancers is currently under investigation in our laboratory.

Altogether, the above findings indicate that the CycHyp signature represents a new generation of prognostic biomarker reflecting a generic environmental condition in tumors that differs from the conventional view of a static, continuous hypoxia occurring in tumors. When applied to breast cancer, the CycHyp signature has a powerful prognostic value independently of molecular risk factors but also offers a unique decision making tool to complement the discrimination of patients based on anatomopathologic evaluation. The CycHyp signature is distinct from conventional hypoxia-related gene signature but also from existing prognostic metagenes, and the rationale behind its discovery supports a potential broad applicability to evaluate cancer patient outcomes.

MATERIALS AND METHODS {#s4}
=====================

Tumor cells {#s4_1}
-----------

Twenty cell lines derived from cancer patients (see [Suppl. Table 1](#SD1){ref-type="supplementary-material"} for details) were submitted to cycling hypoxia (CycHyp), i.e. 24 cycles of 30 min incubation under normoxia and 30 min incubation under hypoxic (1% O~2~) conditions to reproduce tumor hypoxic fluctuations, as previously reported \[[@R5], [@R51]\]. We also considered control conditions of 24 h continuous exposure of tumor cells to either 21% O~2~ (Normoxia) or 1% O~2~ (ContHyp). For each culture condition, cells were immediately snap-frozen at the end of the last incubation period.

Identification of the signatures {#s4_2}
--------------------------------

mRNA extracts from each tumor cell cultured under the three above conditions (normoxia, cycling hypoxia and continuous hypoxia) were analysed by hybridization on Human Gene 1.0 ST Affymetrix microarrays (GEO access number: GSE42416):

<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=probzowmiyseqxm&acc=GSE42416>

The extent of the resulting tumor cell datasets (20 samples in each of the three conditions) led us to resort on a resampling mechanism to increase the robustness of the signatures to be identified. For every resampling experiment, a subset of 90 % of the samples was chosen uniformly at random as a training set and the remaining 10% were used as validation set. Differentially expressed probesets (one probeset = a collection of probes designed to interrogate a given sequence) were assessed on each subset according to a t-test and the corresponding FDR corrected p-values were reported. The 100 probesets with the lowest corrected p-values, averaged over 200 resamplings \[[@R52]-[@R54]\], formed the CycHyp (Table [1](#T1){ref-type="table"}) or ContHyp (Table [2](#T2){ref-type="table"}) signatures. All such expression differences were highly significant (p\<1e-4) after Benjamini-Hochberg FDR correction for the multiplicity of the test \[[@R55]\]. Of note, in each resampling, the 10 % data not used to select probesets allowed one to estimate the discrimination potential between (cycling or continuous) hypoxia versus normoxia conditions. The average classification accuracy over all resamplings amounted to 97.5 % for CycHyp and 94.3% for ContHyp.

The 100 HGU1.0 ST probesets forming the CycHyp signature corresponded to 94 unique Entrez GeneID in the NCBI database, out of which 69 genes were available on the HGU133a platform (i.e., the technology used in most clinical studies considered here). Those 69 genes were represented by 87 HGU133a probesets. The few datasets collected on HGU133plus2 were reduced to the probesets also present on HGU133a.

Patient data sets {#s4_3}
-----------------

All breast cancer expression data were summarized with MAS5 and represented in log2 scale (except for GSE6532 already summarized with RMA). Breast cancer subtypes (ER+/HER2-, ER-/HER2- and HER2+) were identified with the genefu R package \[[@R56]\] (see [Supplementary R Package](#SD1){ref-type="supplementary-material"}). Disease-free survival at 5 years was used as the survival endpoint. The data from all patients were censored at 10 years to have comparable follow-up times across clinical studies \[[@R32]\].

Prognostic models of the clinical outcome {#s4_4}
-----------------------------------------

The VDX dataset (GSE2034 and GSE5327 from the GEO database) was considered as a reference because of its large number of node-negative untreated patients \[[@R17]\]. This dataset formed the training set used to estimate a prognostic model of the clinical outcome. A risk score for each patient was computed from a penalized Cox proportional hazards model \[[@R57]\] implemented in the Penalized R package \[[@R58]\]; the parameters of the elastic net penalty were learned on the training set by cross-validation. Prediction into a high risk *vs.* low risk group resulted from a predefined threshold value on this risk score. The decision threshold was chosen on the training set to maximize the specificity and sensitivity of the discrimination between patients with progressing disease versus disease-free patients at 5 years. Following the methodology described by Haibe-Kains et al. \[[@R32]\], all other datasets were used as validations to assess the prognostic performances on independent samples, i.e. balanced classification rate (BCR), concordance index (CI) \[[@R59]\] and hazard ratio (HR) \[[@R60]\]. The survcomp R packages were used to test the significance of the HR and CI values \[[@R33]\] while a Z-test allowed to infer p-values for the BCR relying on an approximation by a normal distribution.

Prognostic performances of a penalized Cox model defined on the CycHyp signature were also compared with well-established prognosis models for breast cancer, namely Gene 70 (Mammaprint) \[[@R14]\], Gene 76 \[[@R17]\] and Oncotype DX \[[@R15]\] signatures. Those existing signatures were associated to specific prognostic models implemented in the genefu R package \[[@R56]\]. Comparison of CycHyp and ContHyp signatures was also carried out with random gene signatures of the same sizes, i.e. 87 and 123 probesets, respectively. One thousand signatures of each size were generated and analysed using the methodology described by Venet et al. \[[@R11]\]. The objective of those experiments was to assess to which extent the CycHyp and ContHyp signatures had a better discrimination power between risk groups than random signatures. Gene Set Enrichment Assay (GSEA) analysis was also performed using the molecular signature database (MSigDB) and the CycHyp and ContHyp signatures expanded to 2118 and 2065 differentially expressed genes, respectively (after FDR correction and averaged over all resamplings.
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